Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive HBeAg-positive Subjects With Chronic HBV Infection

NCT06990776 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT06990776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive HBeAg-positive Subjects With Chronic HBV Infection
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 2
Overall status
Withdrawn
Start date
July 9, 2025
Completion date
July 17, 2025
Enrollment
0 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b